Jian-Pi-Yi-Shen Decoction Relieves Renal Anemia in 5/6 Nephrectomized Rats: Production of Erythropoietin Via Hypoxia Inducible Factor Signaling

Overview

Journal Evid Based Complement Alternat Med

Specialty Rehabilitation Medicine

Date 2019 Apr 4

PMID 30941190

Citations 9

Authors

Jianping Chen

Fochang Wang

Shiying Huang

Xiaoyan Liu

Zhonggui Li

Airong Qi

Xinhui Liu

Tiegang Yi

Shunmin Li

Affiliations

Soon will be listed here.

Abstract

Jian-Pi-Yi-Shen (JPYS) is one of the herbal medicines for treatment of anemic patients with chronic kidney disease (CKD). However, less of scientific evidence to support JPYS involved in treating anemia has been revealed. Here, an animal study was performed to investigate its hematopoietic activities and the underlying mechanism. The 5/6 nephrectomized inductions of CKD anemic rats were randomly divided into two groups: CKD group and JPYS group. Sham-operated rats served as sham group. JPYS (1.36 g/kg/d) was administered orally to CKD rats daily for six consecutive weeks. Results showed that JPYS treatment notably improved renal function and pathological injury in CKD rats. JPYS also restored the hematological parameters, including red blood cells, hemoglobin, and hematocrit. In parallel, the reduction level of EPO was reversed by JPYS. Furthermore, JPYS induced the accumulation of hypoxia inducible factor (HIF)- protein expression. Collectively, these results provide convincing evidence for JPYS decoction in ameliorating CKD-associated anemia, and its mechanism might be related to regulate EPO production via HIF signaling pathway.

Citing Articles

Astragaloside IV alleviates 1-deoxysphinganine-induced mitochondrial dysfunction during the progression of chronic kidney disease through p62-Nrf2 antioxidant pathway.

Gui T, Chen Q, Li J, Lu K, Li C, Xu B Front Pharmacol. 2023; 14:1092475.

PMID: 37033627 PMC: 10079923. DOI: 10.3389/fphar.2023.1092475.

A Chinese Medicine Compound Alleviates Cisplatin-Induced Acute Kidney Injury via Its Antiapoptosis and Anti-Inflammation Effects in Mice.

He R, Liu J, Chen Y, Liao Y, Wang Y, Jin X Evid Based Complement Alternat Med. 2022; 2022:7841284.

PMID: 35815260 PMC: 9259212. DOI: 10.1155/2022/7841284.

Network Pharmacology and Experimental Verification Strategies to Illustrate the Mechanism of Jian-Pi-Yi-Shen Formula in Suppressing Epithelial-Mesenchymal Transition.

Zhao Y, Li X, Wang F, Huang S, Du H, Li S Front Pharmacol. 2022; 13:873023.

PMID: 35656312 PMC: 9152215. DOI: 10.3389/fphar.2022.873023.

Jian-Pi-Yi-Shen Formula Ameliorates Oxidative Stress, Inflammation, and Apoptosis by Activating the Nrf2 Signaling in 5/6 Nephrectomized Rats.

Zhou F, Zou X, Zhang J, Wang Z, Yang Y, Wang D Front Pharmacol. 2021; 12:630210.

PMID: 33841151 PMC: 8027107. DOI: 10.3389/fphar.2021.630210.

A Review of Edible Jujube, the Fruit: A Heath Food Supplement for Anemia Prevalence.

Chen J, Tsim K Front Pharmacol. 2020; 11:593655.

PMID: 33324222 PMC: 7726020. DOI: 10.3389/fphar.2020.593655.

References

Li S, Foley R, Collins A . Anemia and cardiovascular disease, hospitalization, end stage renal disease, and death in older patients with chronic kidney disease. Int Urol Nephrol. 2005; 37(2):395-402. DOI: 10.1007/s11255-004-3068-2. View

Keithi-Reddy S, Addabbo F, Patel T, Mittal B, Goligorsky M, Singh A . Association of anemia and erythropoiesis stimulating agents with inflammatory biomarkers in chronic kidney disease. Kidney Int. 2008; 74(6):782-90. PMC: 2739585. DOI: 10.1038/ki.2008.245. View

Zaritsky J, Young B, Wang H, Westerman M, Olbina G, Nemeth E . Hepcidin--a potential novel biomarker for iron status in chronic kidney disease. Clin J Am Soc Nephrol. 2009; 4(6):1051-6. PMC: 2689881. DOI: 10.2215/CJN.05931108. View

Heikkila M, Pasanen A, Kivirikko K, Myllyharju J . Roles of the human hypoxia-inducible factor (HIF)-3α variants in the hypoxia response. Cell Mol Life Sci. 2011; 68(23):3885-901. PMC: 11114783. DOI: 10.1007/s00018-011-0679-5. View

Yu X, Fang Y, Liu H, Zhu J, Zou J, Xu X . The balance of beneficial and deleterious effects of hypoxia-inducible factor activation by prolyl hydroxylase inhibitor in rat remnant kidney depends on the timing of administration. Nephrol Dial Transplant. 2012; 27(8):3110-9. DOI: 10.1093/ndt/gfr754. View

Babitt J, Lin H . Mechanisms of anemia in CKD. J Am Soc Nephrol. 2012; 23(10):1631-4. PMC: 3458456. DOI: 10.1681/ASN.2011111078. View

Xu M, Nagati J, Xie J, Li J, Walters H, Moon Y . An acetate switch regulates stress erythropoiesis. Nat Med. 2014; 20(9):1018-26. PMC: 4159437. DOI: 10.1038/nm.3587. View

Palmer S, Saglimbene V, Mavridis D, Salanti G, Craig J, Tonelli M . Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis. Cochrane Database Syst Rev. 2014; (12):CD010590. PMC: 6885065. DOI: 10.1002/14651858.CD010590.pub2. View

Chertow G, Liu J, Monda K, Gilbertson D, Brookhart M, Beaubrun A . Epoetin Alfa and Outcomes in Dialysis amid Regulatory and Payment Reform. J Am Soc Nephrol. 2016; 27(10):3129-3138. PMC: 5042674. DOI: 10.1681/ASN.2015111232. View

10.

Liu X, Wu J, Wang J, Fan J, Feng X, Yu X . Possible role of mitochondrial injury in Caulis Aristolochia manshuriensis-induced chronic aristolochic acid nephropathy. Drug Chem Toxicol. 2016; 40(1):115-124. DOI: 10.1080/01480545.2016.1188303. View

11.

Wyatt C, Drueke T . HIF stabilization by prolyl hydroxylase inhibitors for the treatment of anemia in chronic kidney disease. Kidney Int. 2016; 90(5):923-925. DOI: 10.1016/j.kint.2016.08.016. View

12.

Locatelli F, Fishbane S, Block G, Macdougall I . Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients. Am J Nephrol. 2017; 45(3):187-199. DOI: 10.1159/000455166. View

13.

Fraenkel P . Anemia of Inflammation: A Review. Med Clin North Am. 2017; 101(2):285-296. PMC: 5308549. DOI: 10.1016/j.mcna.2016.09.005. View

14.

Sugahara M, Tanaka T, Nangaku M . Prolyl hydroxylase domain inhibitors as a novel therapeutic approach against anemia in chronic kidney disease. Kidney Int. 2017; 92(2):306-312. DOI: 10.1016/j.kint.2017.02.035. View

15.

Flisinski M, Wisniewska-Chudy E, Brymora A, Stefanska A, Strozecki P, Manitius J . Chronic kidney disease leads to hypoxia inducible factor-1alpha to hypoxia inducible factor-2alpha switch in the gastrocnemius muscle. J Physiol Pharmacol. 2017; 68(3):419-425. View

16.

Wang D, Chen J, Liu X, Zheng P, Song G, Yi T . A Chinese herbal formula, Jian-Pi-Yi-Shen decoction, improves muscle atrophy via regulating mitochondrial quality control process in 5/6 nephrectomised rats. Sci Rep. 2017; 7(1):9253. PMC: 5569107. DOI: 10.1038/s41598-017-10027-4. View

17.

Wang X, Yu S, Jia Q, Chen L, Zhong J, Pan Y . NiaoDuQing granules relieve chronic kidney disease symptoms by decreasing renal fibrosis and anemia. Oncotarget. 2017; 8(34):55920-55937. PMC: 5593534. DOI: 10.18632/oncotarget.18473. View

18.

Fishbane S, Spinowitz B . Update on Anemia in ESRD and Earlier Stages of CKD: Core Curriculum 2018. Am J Kidney Dis. 2018; 71(3):423-435. DOI: 10.1053/j.ajkd.2017.09.026. View

19.

Kaplan J, Sharma N, Dikdan S . Hypoxia-Inducible Factor and Its Role in the Management of Anemia in Chronic Kidney Disease. Int J Mol Sci. 2018; 19(2). PMC: 5855611. DOI: 10.3390/ijms19020389. View

20.

Serocki M, Bartoszewska S, Janaszak-Jasiecka A, Ochocka R, Collawn J, Bartoszewski R . miRNAs regulate the HIF switch during hypoxia: a novel therapeutic target. Angiogenesis. 2018; 21(2):183-202. PMC: 5878208. DOI: 10.1007/s10456-018-9600-2. View